Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer

Introduction

Regional Differences Use of CDK 4 and 6 Inhibitors

CDK 4 and 6 Inhibitors in Germany

CDK 4 and 6 Inhibitors in Spain

CDK 4 and 6 Inhibitors in Italy

Patient Case 1: First-Line ER-Positive MBC Rapidly Recurring on Adjuvant AI Therapy

Case Discussion

PALOMA-3: PFS

PFS Proportional Benefits by Different Variables in MONARCH 2 and MONARCH 3

MONARCH 2 and MONARCH 3 Subgroup Analysis Liver Metastases

Case Conclusion

Patient Case 2: First-Line ER-Positive MBC Rapidly Recurring on Adjuvant AI Therapy

Case Discussion

MONALEESA-7 Time to Response

Case Conclusion

Patient Case 3: First-Line ER-Positive Asymptomatic MBC

Case Discussion

FALCON Trial PFS With and Without Visceral Disease in ITT Population

MONALEESA-2 PFS

CDK 4 and 6 Inhibitors: Providing Therapeutic Benefit in Endocrine-Sensitive Population

CDK 4 and 6 Inhibitors in Elderly Patients

Patient Case 4: First-Line, ER-Positive, Asymptomatic MBC

Case Discussion

CDK 4 and 6 Inhibitors: Providing Therapeutic Benefit in Endocrine-Resistant Population

Patient Case 5: First-Line, ER-Positive, Asymptomatic MBC

Case Discussion

MONALEESA-7: PFS

PALOMA-3: Premenopausal Subgroup

MONARCH 2: Pre-Menopausal Subgroup Analysis

Concluding Remarks

Abbreviations